Literature DB >> 29022836

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

Ashleigh Scott1,2,3, Nicholas Weber3, Campbell Tiley4, Kerry Taylor5, John Taper6, Simon Harrison7, Kah-Lok Chan7, Richard Stark8, Cindy Lee9, Kirk Morris3, P Joy Ho10, Anthony Dodds11, Sundra Ramanathan12, Raj Ramakrishna13, Anne-Marie Watson14, Bradley Auguston15, Fiona Kwok16, Hang Quach17, Pauline Warburton18, Philip Rowlings19, Peter Mollee1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29022836     DOI： 10.1080/10428194.2017.1387911

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.

Authors:  Luca Bertamini; Giuseppe Bertuglia; Stefania Oliva
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

2.  Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Authors:  Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff
Journal:  Eur J Haematol       Date:  2021-11-15       Impact factor: 3.674

3.  Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center.

Authors:  Suresh Kumar Bondili; Bhausaheb Bagal; Abhinav Zawar; Pradeep Ventrapati; Jayashree Thorat; Anant Gokarn; Sachin Punatar; Lingaraj Nayak; Avinash Bonda; Hashmukh Jain; Manju Sengar; Navin Khattry
Journal:  JCO Glob Oncol       Date:  2021-03

4.  Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.

Authors:  Yu-Chin Hung; Jyh-Pyng Gau; Shang-Yi Huang; Bor-Sheng Ko; Chieh-Lin Jerry Teng
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

5.  Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Authors:  Marina Silvia Parisi; Salvatore Leotta; Alessandra Romano; Vittorio Del Fabro; Enrica Antonia Martino; Valeria Calafiore; Rachele Giubbolini; Uros Markovic; Valerio Leotta; Mary Ann Di Giorgio; Daniele Tibullo; Francesco Di Raimondo; Concetta Conticello
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.